Biodexa Pharmaceuticals (BDRX) Net Shares Issued and Repurchased (2020 - 2024)
Biodexa Pharmaceuticals (BDRX) reported Net Shares Issued and Repurchased of -$11551.5 for Q4 2024, down 1030.71% on a YoY basis from $1241.2 in Q1 2024, and down 1030.71% sequentially from $1241.2 in Q4 2023.
Biodexa Pharmaceuticals (BDRX) Net Shares Issued and Repurchased (2020 - 2024) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 4 years of Net Shares Issued and Repurchased data on file, last reported at -$11551.5 in Q4 2024.
- For the quarter ending Q4 2024, Net Shares Issued and Repurchased fell 1030.71% year-over-year to -$11551.5; the trailing twelve-month figure through Dec 2024 stood at -$227152.1 (changed N/A YoY), and the FY2024 full-year result was -$11551.5, down 1028.71% from the prior year.
- Net Shares Issued and Repurchased declined to -$11551.5 in Q4 2024, from $1241.2 in the prior quarter.
- In the past five years, Net Shares Issued and Repurchased ranged from a high of $1241.2 in Q4 2023 to a low of -$208631.3 in Q4 2020.
- A 4-year average of -$56788.0 and a median of -$9881.0 in 2022 frame the typical range for Net Shares Issued and Repurchased.
- Across the five-year window, Net Shares Issued and Repurchased surged 115.12% in 2023 and slumped 1030.71% in 2024, its largest moves.
- Tracing BDRX's Net Shares Issued and Repurchased over 4 years: stood at -$208631.3 in 2020, then surged by 96.06% to -$8210.5 in 2022, then surged by 115.12% to $1241.2 in 2023, then sank by 1030.71% to -$11551.5 in 2024.
- Business Quant data shows BDRX's Net Shares Issued and Repurchased at -$11551.5 in Q4 2024, $1241.2 in Q4 2023, and -$8210.5 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -11,551.52 |
| Dec 31, 2024 | -11,551.52 |
| Dec 31, 2023 | 1,241.15 |
| Dec 31, 2023 | 1,241.15 |
| Dec 31, 2022 | -8,210.50 |
| Dec 31, 2022 | -8,210.50 |
| Dec 31, 2020 | -208,631.26 |
| Dec 31, 2020 | -208,631.26 |